CoChat

HE3286 Reduces Axonal Loss and Preserves Retinal Ganglion Cell Function in Experimental Optic Neuritis

Open access
Khan, Reas S., Dine, Kimberly, Luna, Esteban, Ahlem, Clarence, Shindler, Kenneth S. · 2014 · Investigative Opthalmology & Visual Science

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Abstract

PURPOSE: Optic nerve inflammation, demyelination, and axonal loss are all prominent features of optic neuritis. While corticosteroids hasten visual recovery in optic neuritis, no treatment improves final visual outcomes. HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol), a synthetic derivative of a natural steroid, β-AET (5-androstene-3β,7β,17β-triol), exerts anti-inflammatory effects in several disease models and has purported neuroprotective effects as well. HE3286's ability to suppress optic neuritis was examined in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. METHODS: Experimental autoimmune encephalomyelitis was induced in C57/BL6 mice. Mice were treated daily with intraperitoneal vehicle or 40 mg/kg HE3286. Visual function was assessed by optokinetic responses (OKR) at baseline and every 10 days until euthanasia at 40 days post immunization. Retinas and optic nerves were isolated. Inflammation (hematoxylin and eosin and Iba1 staining), demyelination (Luxol fast blue staining), and axonal loss (neurofilament staining) were assessed in optic nerve sections. Retinal ganglion cells (RGCs) were immunolabeled with Brn3a antibodies to quantify RGC survival. RESULTS: Progressive decreases in OKR occurred in vehicle-treated EAE mice, and HE3286 treatment reduced the level of this vision loss. HE3286 also attenuated the degree of inflammation, demyelination, and axonal loss in EAE optic nerves as compared to nerves from vehicle-treated EAE mice. Retinal ganglion cell loss that occurred in both vehicle- and HE3286-treated EAE mice was reduced in the temporal retinal quadrant of HE3286-treated mice. CONCLUSIONS: HE3286 suppresses inflammation, reduces demyelination and axonal loss, and promotes RGC survival during experimental optic neuritis. Importantly, HE3286 treatment also preserves some RGC function. Results suggest that HE3286 is a potential novel treatment for optic neuritis.

Overview

Integrity signals

Registry

Crossref · 10.1167/iovs.14-14672

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 40 references

Cited by

See all 33

Metadata

Authors
Khan, R. S., Dine, K., Luna, E., Ahlem, C., & Shindler, K. S.
Affiliations
  • University of Pennsylvania (US)
  • Harbor Therapeutics, Inc., San Diego, California, United States
Corresponding author
Shindler, Kenneth S.
Venue
Investigative Opthalmology & Visual Science
Published
2014-09-11
Volume
55
Issue
9
Pages
5744
ISSN
  • 0146-0404 (ISSN-L)
  • 1552-5783
OpenAlex
W2012637873
Cited by
33
References
41
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 2 · 2015: 1
FWCI
1.98
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • Investigative Ophthalmology & Visual Science (publishedVersion, public-domain)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • F. M. Kirby Foundation
  • Research to Prevent Blindness
  • James N. Kirby Foundation
  • National Institutes of Health
  • National Eye Institute (R01EY019014, EY019014, P30EY001583)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
optic neuritis, experimental autoimmune encephalomyelitis, retinal ganglion cell survival, axonal loss, demyelination, neuroprotection, anti-inflammatory steroids, multiple sclerosis model, visual function
MeSH terms
Animals, Anti-Inflammatory Agents, Axons, Dehydroepiandrosterone, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Female, Mice, Inbred C57BL, Optic Neuritis, Retinal Ganglion Cells, Neuroprotective Agents, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.